Physician profile
Sabu Thomas
NPI 1609893239
$104,231.41
in general payments reported to CMS, 2019-2025
6 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29K · 2021: $4,593 · 2022: $9,513 · 2023: $5,489 · 2024: $16K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $4,888 · Travel and Lodging: $3,819 · Food and Beverage: $2,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,410.00 |
| Consulting Fee | $4,887.50 |
| Travel and Lodging | $3,819.35 |
| Food and Beverage | $2,404.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $80,583.85 | 2020-2025 | Wainua, Farxiga |
| Bridgebio Pharma, INC. | $23,232.57 | 2025 | Attruby |
| Abbott Laboratories | $263.93 | 2020-2023 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $84.48 | 2024 | Barostim Neo System |
| Abiomed | $66.58 | 2024 | Impella |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabu Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.